Israel-based Teva Pharmaceutical Industries Ltd (NYSE and TASE: TEVA) has launched a generic version of VESIcare (solifenacin succinate) Tablets, 5mg and 10mg, in the United States, it was reported yesterday.
The products are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Solifenacin Succinate Tablets are contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma and in patients who have demonstrated hypersensitivity to the drug.
VESIcare Tablets have annual sales of more than USD955m in the US, according to IQVIA data as of February 2019.
Annexin Pharmaceuticals receives proposed INN vanexin for ANXV
Henlius and Sandoz expand biosimilars collaboration
Aurisco Pharmaceutical reports successful US FDA inspection
Dr. Reddy's launches first-to-market sugammadex injection in the US
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent